Calbiotech is a worldwide leader in immunoassay development and manufacturing. With over 30 years of experience, the Calbiotech team has established itself as a leader in the industry, offering over 200 products distributed to over 50 countries. Our investments in automation and state-of-the-art technologies help ensure our customers receive high-quality, stable, flexible, automation-ready, and cost effective products and services. Calbiotech's Custom Development team is ready to take your innovation from Pipeline to Production. We have custom developed hundreds of coated microplates, reagents, buffers and other components for pharmaceutical companies, universities and research centers in the
《中国制造2025》的发布,给医疗器械行业带来了一项重大利好政策信息——明确把生物医药及高性能医疗器械作为重点发展的十大领域之一,这无疑令医疗器械行业无比振奋。 《中国制造2025》提出,提高医疗器械的产业化水平,重点发展影像设备、医用机器人等高性能诊疗设备,全降解血管支架等高值医用耗材,可穿戴、远程诊疗等移动医疗产品。实现生物3D打印、诱导多能干细胞等新技术的突破和应用。
在分子生物学快速发展的今天,全球*过500,000位客户通过QIAGEN的样本制备与分析技术,获得基本的生命组成——DNA、RNA和蛋白质的生物学信息,在他们的研究领域取得突破性进展。 在QIAGEN的产品和技术支持下,医生们能够更准确、更快速的诊断疾病,指导治疗。科学家们不断探索生命的奥秘,并将这些知识转化为疗效更好的药物。
becton dickinson[http://www.shijichina.com/goodsid/fenleisan/3444248/1.html]edwards[http://www.shijichina.com/goodsid/fenleisan/3444764/1.html]ibidi[http://www.shijichina.com/goodsid/fenleisan/3446941/1.html]
kamiyabiomedical:
KAMIYA BIOMEDICAL COMPANY was founded by Kohji Kamiya in March of 1983 in Thousand Oaks, California and relocated to Seattle, Washington in 1996. Our company's purpose is supplying the life science and medical communities with innovative laboratory research and diagnostic tools of the highest quality. KAMIYA is an independent American company that serves worldwide markets.
The company's first life science products were the cutting edge protein kinase inhibitors staurosporine and K252a for signal transduction research. In 1990, KAMIYA became the first company to introduce anti-Fas monoclonal antibodies to the U.S. for apoptosis research.
U.S. and around the world.